(BNTX) BioNTech SE - Overview
Stock: Cancer Immunotherapies
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 47.5% |
| Relative Tail Risk | -16.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.03 |
| Alpha | -22.03 |
| Character TTM | |
|---|---|
| Beta | 0.966 |
| Beta Downside | 0.402 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.92% |
| CAGR/Max DD | -0.15 |
Description: BNTX BioNTech SE December 17, 2025
BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm founded in 2008 and headquartered in Mainz. It focuses on developing and commercializing mRNA-based immunotherapies for cancer and infectious diseases, and trades as a common stock under the ticker BNTX in the Biotechnology sub-industry.
The company’s pipeline is heavily weighted toward oncology, with dozens of candidates spanning early to late-stage trials. Notable programs include BNT111 (Phase 2 for advanced melanoma), BNT122/RO7198457 (Phase 2 adjuvant trials in high-risk muscle-invasive urothelial carcinoma, colorectal and pancreatic cancers, plus advanced melanoma), BNT311/GEN1046 (ac-asunlimab, currently in Phase 3 for solid tumors), and BNT327 (a multi-indication platform covering small-cell lung cancer, triple-negative breast cancer, neuroendocrine neoplasms, malignant mesothelioma, EGFR-mutant NSCLC, hepatocellular carcinoma, and other solid tumors across Phases 1-3). Early-stage candidates such as BNT211 (CLDN6+ solid tumors) and BNT221 (general oncology) further broaden the portfolio.
Recent financial data show Q4 2024 revenue of approximately $1.9 billion, with COVID-19 vaccine sales still accounting for roughly 30 % of total revenue despite a multi-year decline. R&D expenditure remains high at about €1.2 billion (≈45 % of revenue), reflecting the capital-intensive nature of mRNA oncology development. The broader mRNA oncology market is projected to grow at a CAGR of ~15 % through 2030, driven by increasing regulatory acceptance and expanding pipeline activity across the sector.
For a deeper quantitative assessment of BNTX’s risk-adjusted upside, the ValueRay platform offers a concise, data-driven dashboard worth checking out.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -571.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -9.24 > 1.0 |
| NWC/Revenue: 431.7% < 20% (prev 525.1%; Δ -93.44% < -1%) |
| CFO/TA -0.02 > 3% & CFO -336.1m > Net Income -571.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (239.2m) vs 12m ago -2.21% < -2% |
| Gross Margin: 82.49% > 18% (prev 0.84%; Δ 8165 % > 0.5%) |
| Asset Turnover: 14.41% > 50% (prev 13.57%; Δ 0.84% > 0%) |
| Interest Coverage Ratio: -28.11 > 6 (EBITDA TTM -103.3m / Interest Expense TTM 17.3m) |
Altman Z'' 10.00
| A: 0.64 (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b |
| B: 0.86 (Retained Earnings 18.27b / Total Assets 21.34b) |
| C: -0.02 (EBIT TTM -486.7m / Avg Total Assets 21.87b) |
| D: 6.45 (Book Value of Equity 18.49b / Total Liabilities 2.86b) |
| Altman-Z'' Score: 13.60 = AAA |
Beneish M -2.98
| DSRI: 0.56 (Receivables 699.7m/1.20b, Revenue 3.15b/3.04b) |
| GMI: 1.02 (GM 82.49% / 84.31%) |
| AQI: 1.63 (AQ_t 0.20 / AQ_t-1 0.12) |
| SGI: 1.04 (Revenue 3.15b / 3.04b) |
| TATA: -0.01 (NI -571.6m - CFO -336.1m) / TA 21.34b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of BNTX shares?
Over the past week, the price has changed by -1.92%, over one month by +19.38%, over three months by +8.67% and over the past year by -5.90%.
Is BNTX a buy, sell or hold?
- StrongBuy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BNTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 142.8 | 25.6% |
| Analysts Target Price | 142.8 | 25.6% |
| ValueRay Target Price | 108.9 | -4.2% |
BNTX Fundamental Data Overview January 29, 2026
P/E Forward = 7.0373
P/S = 9.4992
P/B = 1.3515
P/EG = 0.0449
Revenue TTM = 3.15b EUR
EBIT TTM = -486.7m EUR
EBITDA TTM = -103.3m EUR
Long Term Debt = 192.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 53.4m EUR (from shortTermDebt, last quarter)
Debt = 245.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 10.90b EUR (25.18b + Debt 245.4m - CCE 14.53b)
Interest Coverage Ratio = -28.11 (Ebit TTM -486.7m / Interest Expense TTM 17.3m)
EV/FCF = -19.37x (Enterprise Value 10.90b / FCF TTM -562.7m)
FCF Yield = -5.16% (FCF TTM -562.7m / Enterprise Value 10.90b)
FCF Margin = -17.85% (FCF TTM -562.7m / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 82.49% ((Revenue TTM 3.15b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 90.24% (prev 70.71%)
Tobins Q-Ratio = 0.51 (Enterprise Value 10.90b / Total Assets 21.34b)
Interest Expense / Debt = 0.16% (Interest Expense 399.1k / Debt 245.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -384.5m (EBIT -486.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = 95.33 (negative EBITDA) (Net Debt -9.85b / EBITDA -103.3m)
Debt / FCF = 17.50 (negative FCF - burning cash) (Net Debt -9.85b / FCF TTM -562.7m)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.61% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -2.56% (EBIT -486.7m / Capital Employed (Equity 18.83b + L.T.Debt 192.0m))
RoIC = -2.01% (negative operating profit) (NOPAT -384.5m / Invested Capital 19.10b)
WACC = 9.38% (E(25.18b)/V(25.43b) * Re(9.47%) + D(245.4m)/V(25.43b) * Rd(0.16%) * (1-Tc(0.21)))
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.38%
Fair Price DCF = unknown (Cash Flow -562.7m)
EPS Correlation: -72.46 | EPS CAGR: -35.01% | SUE: 0.21 | # QB: 0
Revenue Correlation: -59.93 | Revenue CAGR: -29.16% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-2.18 | Chg30d=-0.153 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.35 | Chg30d=+0.003 | Revisions Net=-1 | Growth EPS=+31.1% | Growth Revenue=-4.1%